

Notice of Annual Meeting of Shareholders 2025

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (**AFT** or the **Company**) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on **Friday, 1 August 2025 commencing at 10.30am** (New Zealand time).

Agenda

A Addresses

Our Chairman, David Flacks, and our Founder and Chief Executive Officer, Hartley Atkinson, will provide an overview of the Company's performance for the year ended 31 March 2025. There will also be an opportunity for shareholders to ask questions.

B Resolutions

Shareholders will be asked to consider, and if thought fit, pass the following **ordinary resolutions**:

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2026 financial year.
2. That Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited.
3. That Allison Yorston be elected as a director of AFT Pharmaceuticals Limited.

Each resolution is an ordinary resolution and must be approved by a simple majority of the votes of those shareholders entitled to vote and voting on the resolution.

See explanatory notes on each resolution below. No shareholder is restricted from voting on any resolution.

The Board recommends unanimously that you vote in favour of all resolutions.

C General Business

To consider any other matter that may be brought properly before the Annual Meeting.

By Order of the AFT Pharmaceuticals Limited Board

David Flacks
Chairman

27 June 2025

Resolution 1: Auditor's Remuneration

Deloitte is automatically reappointed auditor of the Company at the Annual Meeting pursuant to the Companies Act 1993. The resolution sought is to authorise the directors to fix the remuneration of the auditor pursuant to section 207(S)(a) of the Companies Act 1993.

Resolution 2: Re-election of Dr Hartley Atkinson as a Director

Hartley was appointed as an executive director by the shareholders of AFT on 4 September 1997 and was last re-elected in 2022. In accordance with the applicable NZX listing rules, Hartley retires by rotation and, being eligible, offers himself for re-election as a director of AFT at the meeting. The Board unanimously supports Hartley's re-election and considers Hartley to be a non-independent director as he is an executive officer and majority shareholder of AFT.

Dr Hartley Atkinson **Founder, Executive Director and Chief Executive Officer**

Hartley founded AFT in 1997. Before founding AFT, Hartley worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, Hartley was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. Hartley holds a Doctorate in Pharmacology, a Masters in Pharmaceutical Chemistry with distinction, and a Degree in Pharmacy, all from the University of Otago.

Hartley is the current Chief Executive Officer and a majority shareholder of AFT.

Resolution 3: Election of Allison Yorston as a Director

Allison was appointed as a director by the Board on 12 November 2024. In accordance with the applicable NZX listing rules, Allison retires and, being eligible, offers herself for election as a director of AFT at the meeting. The Board unanimously supports Allison's election and considers Allison to be an independent director.

Allison Yorston **Independent Director**

Allison brings to AFT more than 20 years of blue-chip fast-moving consumer goods, telecommunications and retail marketing experience gained across Australia and New Zealand at senior management and C-suite levels. She has managed brand turnarounds and grown and developed marketing teams to deliver share gains in competitive markets and is experienced at managing multi-brand portfolios including both product and corporate brands. She is currently Director of Marketing at Griffins Snacks and is a former Director of the Australian Beverages Council and a former Chief Marketing Officer at Suntory Beverage & Food Oceania. Prior to Suntory she held senior marketing roles at Vodafone, Fonterra and Sanitarium. Allison is a Graduate of the Australian Institute of Company Directors Course and a member of the AICD.

Attendance at Meeting

All shareholders registered on the Company's share register at 5pm Wednesday 30 July 2025 are entitled to attend and vote at the meeting.

Voting and Proxies

Voting at the meeting shall be by way of a poll of the Company's shareholders entitled to vote and voting.

A shareholder entitled to attend and vote at the meeting can appoint a proxy to attend and vote on that shareholder's behalf. A proxy need not be a shareholder. The Chair of the meeting may be appointed to act as proxy.

If the Chair of the meeting is appointed to act as proxy and is not directed how to vote, the Chair will vote in favour of all the resolutions.

If you do not name a person as your proxy but otherwise complete the proxy form in full or your named proxy does not attend the meeting, the Chairman will act as your proxy and will only vote in accordance with your express direction.

A shareholder wishing to appoint a proxy can do so by visiting www.investorvote.co.nz. Shareholders will be required to enter their CSN/Holder Number and postcode or country of residence to complete the online appointment.

Alternatively, shareholders can appoint a proxy by completing the enclosed proxy form and returning it to Computershare Investor Services Limited by any of the methods specified on the proxy form.

The proxy form must be received no later than 10.30am on Wednesday 30 July 2025 (being 48 hours prior to the meeting).

Webcast

The Annual Meeting will be webcast live. To view and listen to the webcast, please visit [AFT 2025 Annual Meeting webcast](#)

- <https://webcast.openbriefing.com/afp-agm-2025/>

Note that shareholders joining by webcast will not be able to vote at the meeting or ask questions. In order to vote you will need to appoint a proxy in accordance with the above instructions before 10.30am on Wednesday 30 July 2025.

If you have any questions you would like considered at the meeting, please send them to investor.relations@aftpharm.com in advance of the meeting.

More Information

If you have any questions, or for more information, please contact AFT's Company Secretary, at investor.relations@aftpharm.com